TY - T1的抗结核混乱关系的预测atment duration based on a 22-gene transcriptomic model JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.03492-2020 VL - 58 IS - 3 SP - 2003492 AU - Heyckendorf, Jan AU - Marwitz, Sebastian AU - Reimann, Maja AU - Avsar, Korkut AU - DiNardo, Andrew R. AU - Günther, Gunar AU - Hoelscher, Michael AU - Ibraim, Elmira AU - Kalsdorf, Barbara AU - Kaufmann, Stefan H.E. AU - Kontsevaya, Irina AU - van Leth, Frank AU - Mandalakas, Anna M. AU - Maurer, Florian P. AU - Müller, Marius AU - Nitschkowski, Dörte AU - Olaru, Ioana D. AU - Popa, Cristina AU - Rachow, Andrea AU - Rolling, Thierry AU - Rybniker, Jan AU - Salzer, Helmut J.F. AU - Sanchez-Carballo, Patricia AU - Schuhmann, Maren AU - Schaub, Dagmar AU - Spinu, Victor AU - Suárez, Isabelle AU - Terhalle, Elena AU - Unnewehr, Markus AU - Weiner, January AU - Goldmann, Torsten AU - Lange, Christoph Y1 - 2021/09/01 UR - //www.qdcxjkg.com/content/58/3/2003492.abstract N2 - Background The World Health Organization recommends standardised treatment durations for patients with tuberculosis (TB). We identified and validated a host-RNA signature as a biomarker for individualised therapy durations for patients with drug-susceptible (DS)- and multidrug-resistant (MDR)-TB.Methods Adult patients with pulmonary TB were prospectively enrolled into five independent cohorts in Germany and Romania. Clinical and microbiological data and whole blood for RNA transcriptomic analysis were collected at pre-defined time points throughout therapy. Treatment outcomes were ascertained by TBnet criteria (6-month culture status/1-year follow-up). A whole-blood RNA therapy-end model was developed in a multistep process involving a machine-learning algorithm to identify hypothetical individual end-of-treatment time points.Results 50 patients with DS-TB and 30 patients with MDR-TB were recruited in the German identification cohorts (DS-GIC and MDR-GIC, respectively); 28 patients with DS-TB and 32 patients with MDR-TB in the German validation cohorts (DS-GVC and MDR-GVC, respectively); and 52 patients with MDR-TB in the Romanian validation cohort (MDR-RVC). A 22-gene RNA model (TB22) that defined cure-associated end-of-therapy time points was derived from the DS- and MDR-GIC data. The TB22 model was superior to other published signatures to accurately predict clinical outcomes for patients in the DS-GVC (area under the curve 0.94, 95% CI 0.9–0.98) and suggests that cure may be achieved with shorter treatment durations for TB patients in the MDR-GIC (mean reduction 218.0 days, 34.2%; p<0.001), the MDR-GVC (mean reduction 211.0 days, 32.9%; p<0.001) and the MDR-RVC (mean reduction of 161.0 days, 23.4%; p=0.001).Conclusion Biomarker-guided management may substantially shorten the duration of therapy for many patients with MDR-TB.A 22-gene RNA-based model predicts individual durations of antimicrobial therapy for patients treated for tuberculosis. Application of this model will potentially shorten treatment duration in the majority of patients with MDR-TB. https://bit.ly/36dZOq0 ER -